Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in Coronary Artery Disease
NCT01165931Phase 2Withdrawn
- Sponsor
- Bayer
- Start
- May 2012
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of riociguat in coronary artery disease (CAD), sponsored by Bayer. Primary endpoint: Ratio of coronary blood flow after Riociguat to adenosine compared to nitroglycerin. Planned start May 2012; status: withdrawn.
02
Drugs
riociguat
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01165931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01165931.